


**An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy**

## Primary Endpoints

- PFS
- OS



# Trial Schema

**Sponsor:** University College London

**Recruitment target:** 618

## **Study Objectives**

To assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance of olaparib alone in patients who have received combination platinum-based chemotherapy

## **Primary Endpoints**

PFS (RECIST v1.1) and OS (death from any cause), measured from randomisation

## **Updates**

- 35 UK sites, 58 international sites from 7 countries
- 6 UK sites open; Australian sites in set-up
- First site activated: 15/06/2018
- FPI: 01/08/2018;
- 3 patients randomised

